Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MPC2 | O95563 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568729 | 0.91 | PPARG (0.49) | PPARGFFAR1THRATHRBCA2 | |
| SCHEMBL2570731 | 0.91 | PPARG (0.49) | PPARGFFAR1THRATHRBCA2 | |
| SCHEMBL1384327 | 0.90 | THRA (0.50) | PPARGFFAR1THRATHRBCA2 | |
| SCHEMBL526756 | 0.88 | PPARG (0.53) | PPARGFFAR1THRATHRBMPC2 | |
| SCHEMBL1386640 | 0.88 | PPARG (0.53) | PPARGFFAR1THRATHRBMPC2 | |
| SCHEMBL1386923 | 0.87 | PPARG (0.47) | PPARGFFAR1THRATHRBCA2 | |
| Hydrochloric Acid SCHEMBL3871967 | 0.87 | PPARG (0.52) | PPARGFFAR1THRATHRBMPC2 | |
| Hydrochloric Acid SCHEMBL3871964 | 0.87 | PPARG (0.52) | PPARGFFAR1THRATHRBMPC2 | |
| Hydrochloric Acid SCHEMBL2573831 | 0.87 | PPARG (0.52) | PPARGFFAR1THRATHRBMPC2 | |
| SCHEMBL1385853 | 0.87 | PPARG (0.46) | PPARGFFAR1THRATHRBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | claimed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | claimed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | claimed |
| EP-1583529-B1 | AMINO ACID PHENOXY ETHERS, THEIR PREPARATION AND USES | BEXEL PHARMACEUTICALS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| WO-2006125285-A1 | INSULIN SENSITIZATION TO SLOW DOWN PUBERTAL TEMPO AND TO AUGMENT PUBERTAL GROWTH | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2006-11-30 | — | — | WO | disclosed |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | BEXEL PHARMACEUTICALS, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6794401-B2 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; metabolic Syndrome-X; immunological diseases, inflammation, obesity, hyperlipidemia, hypertension, diabetes; increased leptin level; no liver toxicity; inhibits TNF alpha , IL-6 and IL-1 beta; no affinity for PPAR-g; non-adipogenic | BEXEL PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| WO-2004066964-A9 | AMINO ACID PHENOXY ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040142991-A1 | Amino acid phenoxy ethers | BEXEL PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142991-A1 | Amino acid phenoxy ethers | IL4I1, DNPEP, GPR119 | PPARG 35/4885FFAR1 87/4885THRA 718/4885 |
| US-20050096366-A1 | thiazolidin-2,4-diones or -oxazolidin-2,4-diones; obesity, inflammation, autoimmune diseases (multiple sclerosis and rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic. | PPARA, PPARG, PPARD | PPARG 2/4885FFAR1 26/4885THRA 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.